CANTHARIDIN

CANTHARIDIN was reported 183 times

CANTHARIDIN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 APPLICATION SITE PLAQUE 1 0.0435
1 CRYOTHERAPY 1 0.0135
2 APPLICATION SITE VESICLES 78 0.0120
3 SKIN TEMPERATURE INCREASED 1 0.0118
4 BLISTER RUPTURE 8 0.0108
5 PRODUCT ADMINISTERED BY WRONG PERSON 4 0.0105
6 PRODUCT ADMINISTERED FROM UNAUTHORISED PROVIDER 1 0.0096
7 APPLICATION SITE INFECTION 4 0.0079
8 APPLICATION SITE WOUND 1 0.0061
9 CHEMICAL BURN 6 0.0052
10 MUCOSAL INFECTION 1 0.0043
11 URINARY BLADDER RUPTURE 1 0.0039
12 CHEMICAL BURNS OF EYE 1 0.0036
13 INCREASED DOSE ADMINISTERED 1 0.0032
14 APPLICATION SITE BURN 12 0.0024
15 APPLICATION SITE PAIN 53 0.0024
16 IMPETIGO 3 0.0020
17 APPLICATION SITE DISCOMFORT 3 0.0017
18 BLOOD BLISTER 5 0.0016
19 APPLICATION SITE SCAR 2 0.0016
20 ACTIVITIES OF DAILY LIVING DECREASED 1 0.0016
21 APPLICATION SITE EROSION 2 0.0016
22 DRUG MONITORING PROCEDURE INCORRECTLY PERFORMED 1 0.0015
23 PRODUCT KNOWLEDGE DEFICIT 1 0.0013
24 BLISTER INFECTED 1 0.0013
25 SKIN BACTERIAL INFECTION 1 0.0012
26 DRUG LEVEL FLUCTUATING 1 0.0011
27 ANOGENITAL WARTS 1 0.0011
28 APPLICATION SITE HAEMORRHAGE 3 0.0011
29 ULNA FRACTURE 1 0.0010
30 APPLICATION SITE PAPULES 1 0.0009
31 APPLICATION SITE SCAB 2 0.0009
32 EPSTEIN-BARR VIRAEMIA 1 0.0009
33 PRODUCT PACKAGE ASSOCIATED INJURY 2 0.0009
34 APPLICATION SITE DISCHARGE 1 0.0009
35 STAPHYLOCOCCAL SKIN INFECTION 1 0.0008
36 APPLICATION SITE WARMTH 1 0.0008
37 APPLICATION SITE DISCOLOURATION 3 0.0007
38 LIP BLISTER 2 0.0007
39 EFFUSION 1 0.0007
40 HYPERURICAEMIA 3 0.0007
41 CORNEAL ABRASION 1 0.0007
42 APPLICATION SITE INFLAMMATION 1 0.0007
43 SUPERINFECTION 1 0.0007
44 TREATMENT DELAYED 1 0.0006
45 BURNS SECOND DEGREE 1 0.0006
46 APPLICATION SITE REACTION 4 0.0006
47 PRODUCT DELIVERY MECHANISM ISSUE 3 0.0006
48 PRODUCT PHYSICAL CONSISTENCY ISSUE 3 0.0005
49 BLISTER 30 0.0005
50 APPLICATION SITE URTICARIA 1 0.0004
51 SKIN TIGHTNESS 2 0.0004
52 THERMAL BURN 3 0.0004
53 RENAL TUBULAR DISORDER 1 0.0004
54 NON-CARDIAC CHEST PAIN 1 0.0003
55 SCREAMING 2 0.0003
56 SKIN EROSION 1 0.0003
57 DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 1 0.0003
58 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 1 0.0003
59 SKIN INJURY 1 0.0003
60 LIQUID PRODUCT PHYSICAL ISSUE 2 0.0003
61 APPLICATION SITE ERYTHEMA 7 0.0003
62 SKIN PAPILLOMA 1 0.0002
63 APPLICATION SITE EXFOLIATION 1 0.0002
64 PRODUCT COMMUNICATION ISSUE 2 0.0002
65 THERAPEUTIC PRODUCT EFFECT DELAYED 1 0.0002
66 SKIN ABRASION 1 0.0002
67 KIDNEY TRANSPLANT REJECTION 1 0.0002
68 VULVOVAGINAL PAIN 1 0.0002
69 HYPERCHOLESTEROLAEMIA 2 0.0002
70 FLUID INTAKE REDUCED 1 0.0002
71 ERYSIPELAS 1 0.0002
72 PRODUCT COLOUR ISSUE 1 0.0002
73 SKIN LACERATION 2 0.0002
74 APPLICATION SITE PRURITUS 4 0.0002
75 MUSCLE RIGIDITY 2 0.0002
76 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1 0.0002
77 PRESCRIPTION DRUG USED WITHOUT A PRESCRIPTION 1 0.0002
78 APPLICATION SITE IRRITATION 2 0.0002
79 SWELLING OF EYELID 1 0.0002
80 PRODUCT LABEL ISSUE 1 0.0001
81 SKIN REACTION 2 0.0001
82 FURUNCLE 1 0.0001
83 SKIN PLAQUE 1 0.0001
84 ANAL INCONTINENCE 1 0.0001
85 PRODUCT DISTRIBUTION ISSUE 1 0.0001
86 WOUND 3 0.0001
87 POST PROCEDURAL COMPLICATION 2 0.0001
88 INABILITY TO AFFORD MEDICATION 1 0.0001
89 INJURY ASSOCIATED WITH DEVICE 2 0.0001
90 SCRATCH 1 0.0001
91 SKIN INFECTION 1 0.0001
92 SCAB 1 0.0001
93 PRODUCT PRESCRIBING ERROR 2 0.0001
94 CRYING 3 0.0001
95 NO THERAPEUTIC RESPONSE 1 0.0001
96 SECRETION DISCHARGE 1 0.0001
97 DRUG RESISTANCE 2 0.0001
98 APPLICATION SITE RASH 1 0.0001
99 SKIN DISORDER 2 0.0001
100 SKIN EXFOLIATION 5 0.0001
101 CIRCULATORY COLLAPSE 1 0.0001
102 SCAR 1 0.0001
103 ACCIDENTAL EXPOSURE TO PRODUCT 6 0.0001
104 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 1 0.0001
105 THINKING ABNORMAL 1 0.0001
106 BACTERIAL INFECTION 1 0.0001
107 LETHARGY 3 0.0001
108 SKIN FISSURES 1 0.0001
109 EXTRA DOSE ADMINISTERED 2 0.0000
110 HYPERSENSITIVITY 8 0.0000
111 PAIN OF SKIN 1 0.0000
112 DEVICE DELIVERY SYSTEM ISSUE 1 0.0000
113 PAIN IN JAW 1 0.0000
114 DISCOMFORT 2 0.0000
115 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 6 0.0000
116 BURNING SENSATION 2 0.0000
117 LYMPHADENOPATHY 1 0.0000
118 PRODUCT USE ISSUE 5 0.0000
119 DYSPNOEA EXERTIONAL 1 0.0000
120 ACUTE KIDNEY INJURY 4 0.0000
121 PAIN 16 0.0000
122 DISORIENTATION 1 0.0000
123 DEVICE BREAKAGE 1 0.0000
124 TREATMENT FAILURE 2 0.0000
125 RENAL IMPAIRMENT 2 0.0000
126 ADVERSE DRUG REACTION 2 0.0000
127 THERAPY NON-RESPONDER 1 0.0000
128 RENAL DISORDER 1 0.0000
129 DISEASE RECURRENCE 1 0.0000
130 RASH ERYTHEMATOUS 1 0.0000
131 HAEMORRHAGE 2 0.0000
132 ECZEMA 1 0.0000
133 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
134 URTICARIA 3 0.0000
135 GAIT DISTURBANCE 3 0.0000
136 LOSS OF CONSCIOUSNESS 2 0.0000
137 PYREXIA 5 0.0000
138 INFECTION 2 0.0000
139 DRUG INTERACTION 2 0.0000
140 DRY MOUTH 1 0.0000
141 ADVERSE EVENT 1 0.0000
142 OROPHARYNGEAL PAIN 1 0.0000
143 DRUG INTOLERANCE 1 0.0000
144 SYNCOPE 1 0.0000
145 CHEST DISCOMFORT 1 0.0000
146 SEIZURE 1 0.0000
147 ABDOMINAL PAIN 2 0.0000
148 DISEASE PROGRESSION 1 0.0000
149 PRODUCT QUALITY ISSUE 1 0.0000
150 PARAESTHESIA 1 0.0000
151 CONFUSIONAL STATE 1 0.0000
152 COVID-19 1 0.0000
153 NASOPHARYNGITIS 1 0.0000
154 DRUG INEFFECTIVE 7 0.0000
155 ANAEMIA 1 0.0000
156 ERYTHEMA 1 0.0000
157 OVERDOSE 1 0.0000
158 RASH 2 0.0000
159 OFF LABEL USE 4 0.0000
160 MALAISE 2 0.0000
161 VOMITING 2 0.0000
162 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
163 FATIGUE 3 0.0000
164 NAUSEA 3 0.0000
165 COUGH 1 0.0000
166 PRODUCT DOSE OMISSION ISSUE 1 0.0000
167 CONDITION AGGRAVATED 1 0.0000
168 DIARRHOEA 2 0.0000
169 DIZZINESS 1 0.0000
170 DYSPNOEA 1 0.0000